A Compendium of Syngeneic, Transplantable Pediatric High-Grade Glioma Models Reveals Subtype-Specific Therapeutic Vulnerabilities is a research paper published in Cancer Discovery (2023). On theSindex it has a DataRank of 0.533. It has been cited 34 times.
Scored on demand from live citation data
Linked data & code
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
0.533
From this paper's citation signal
Citation Network Contribution
0
Citation network not refreshed for this result
This paper's DataRank is currently driven only by its base citation score. Citation network data was not refreshed for this result.
Learn more about DataRank methodology →Canadian Institutes of Health Research
Grant: FDN-154307
National Institutes of Health
Grant: P01-CA196539
Canadian Institutes of Health Research
Grant: PJT-156086
Natural Sciences and Engineering Research Council of Canada
Grant: RGPIN-2016-04911
Cancer Research UK
Grant: RCCCEA-May22\100003
Brain Research UK
Grant: 202021-28
Great Ormond Street Hospital Charity
Grant: V4020
Natural Sciences and Engineering Research Council of Canada
Grant: unidentified
unidentified
National Institutes of Health
Grant: 5P01CA196539-03
Oncohistones: Role of Histone H3 Mutations in the Oncogenesis of Pediatric Cancers
NCI NIH HHS
Grant: P01 CA196539
FWCI
5.67
Citation Percentile
1.0%
Citation Trend
Fields of Study
MeSH Terms
Keywords
Sustainable Development Goals
Additional file 1 of A novel intronic circular RNA circFGFR1int2 up-regulates FGFR1 by recruiting transcriptional activators P65/FUS and suppressing miR-4687-5p to promote prostate cancer progression
Additional file 1 of A novel intronic circular RNA circFGFR1int2 up-regulates FGFR1 by recruiting transcriptional activators P65/FUS and suppressing miR-4687-5p to promote prostate cancer progression